 | • レポートコード：B-MOR-08137 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、避妊薬の世界市場について調べ、避妊薬の世界規模、市場動向、市場環境、ホルモンのタイプ別（プロゲステロン、複合ピル、エストロゲンピル）分析、年齢層別（24歳未満、22歳～35歳、36歳以上）分析、カテゴリ別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・避妊薬の世界市場インサイト ・避妊薬の世界市場環境 ・避妊薬の世界市場動向 ・避妊薬の世界市場規模 ・避妊薬の世界市場規模：ホルモンのタイプ別（プロゲステロン、複合ピル、エストロゲンピル） ・避妊薬の世界市場規模：年齢層別（24歳未満、22歳～35歳、36歳以上） ・避妊薬の世界市場規模：カテゴリ別 ・避妊薬の世界市場：地域別市場規模・分析 ・避妊薬の北米市場規模・予測 ・避妊薬のアメリカ市場規模・予測 ・避妊薬のヨーロッパ市場規模・予測 ・避妊薬のアジア市場規模・予測 ・避妊薬の日本市場規模・予測 ・避妊薬の中国市場規模・予測 ・避妊薬のインド市場規模・予測 ・避妊薬の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global contraceptive pills market was valued at around USD 1 billion in 2017 and is projected to witness a CAGR of approximately 9% during the forecast period of 2018–2023. China, the world’s most populated country, with a population of around 1.36 billion, has one of the highest rates of contraceptives usage.
Need to Prevent Unwanted Abortions
Unwanted pregnancies are on the rise, globally. Government bodies of various countries have been taking measures, like promoting the use of contraceptive pills to prevent this unwanted growth. It is estimated that among the number of pregnancies that occur in the United States, nearly 76% of them are unwanted and are under the age of 30. According to Harvard researchers, it is estimated that single parenthood due to unwanted pregnancies is the reason for holding out on economic mobility, more than other variables like education and race. Given the widespread implications of unwanted pregnancies, the market for contraceptive pills is expected to experience a surge during the forecast period. Also, other factors, like the ease of use of contraceptive pills and their low cost will drive the market.
Limited Access to Contraception
Access to safe, voluntary family planning is a human right. Family planning is central to gender equality and women’s empowerment and is a key factor in reducing poverty. Millions of women are unable to prevent unwanted pregnancies, which is impacting their lifestyle, as well as that of the child, both economically and socially. This is happening primarily due to the lack of knowledge and limited access to contraception and is more prevalent among low and middle-income nations of the world. An estimated 69 countries face the problem of access to contraception. Lack of awareness and limited supply has been one of the major reasons for the contraceptive pills market’s limited growth in the developing nations. Apart from these, issues like cultural and religious opposition prohibit women from consuming certain contraceptive pills, which is also restraining the growth of the global contraceptive pills market.
United States Holds the Largest Market Share
There were approximately 60 million women in the United States in their child-bearing years (age 15 – 44), as of 2017. Around 70% of these women were at risk of unintended pregnancy. More than 99% of women aged between 15 – 44 years have used at least one contraceptive method. This indicates the high awareness and demand for avoiding unintended pregnancies in the United States. The use of contraceptive pills accounts for largest expenditure on contraceptive methods in the United States, followed closely by the use of female sterilization methods, and male condoms.
Major Players: AGILE THERAPEUTICS, BAYER HEALTHCARE, CHURCH & DWIGHT CO., INC., JOHNSON & JOHNSON LTD, LUPIN PHARMACEUTICALS LTD, MERCK & CO., MYLAN LABORATORIES, NOVARTIS, PFIZER AND TEVA PHARMACEUTICALS LTD, among others.
Reasons to Purchase the Report
• To understand the current and future contraceptive pills market outlook in the developed and emerging markets.
• Analyzing various perspectives of the market with the help of Porter’s Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3 month analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Growing Awareness about Contraceptive Pills
6.1.2 Ease of Use and Low Cost
6.1.3 Need to Prevent Unwanted Abortions
6.1.4 Immediate Health Benefits Other than Birth Control
6.1.5 Government Subsidies on Contraceptive Pills
6.2 Restraints
6.2.1 Side Effects Associated with the Use of Contraceptive Drugs
6.2.2 Cultural or Religious Opposition
6.2.3 Limited Access to Contraception
6.2.4 Increased Usage of Alternative Birth Control Method
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Hormone Type
7.1.1 Progestin Pills
7.1.2 Combination Pills
7.1.2.1 Monophasic
7.1.2.2 Triphasic
7.1.2.3 Others
7.1.3 Emergency Pills
7.2 By Age-group Usage
7.2.1 Under 24 Years
7.2.2 Between 22 – 35 Years
7.2.3 Above 36 Years
7.3 By Category
7.3.1 Generic
7.3.2 Branded
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.1.4 Rest of North America
7.4.2 Europe
7.4.2.1 United Kingdom
7.4.2.2 Germany
7.4.2.3 France
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 Gcc
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Agile Therapeutics
9.2 Bayer Healthcare
9.3 Church & Dwight Co., Inc.
9.4 Johnson & Johnson Ltd
9.5 Lupin Pharmaceuticals Ltd
9.6 Merck & Co.
9.7 Mylan Laboratories
9.8 Novartis
9.9 Pfizer
9.10 Teva Pharmaceuticals Ltd
9.11 List not Exhaustive
10. Future of the Market